KAI Chooses OpenClinica Enterprise for Phase I–IV Clinical Trials
OpenClinica, LLC has announced that Rockville, MD-based KAI Research, Inc., (KAI), an Altarum Company, has selected the OpenClinica Enterprise Edition to power Phase I – IV clinical trials. Founded in 1986, KAI is a full service contract research organization (CRO) that provides innovative, cost-effective, and practical support to pharmaceutical, biotech and academic institutions, and the National Institutes of Health (NIH).
The OpenClinica software enhances clinical trials by streamlining electronic data capture (EDC) and clinical data management. The result is higher quality and faster access to the data.
“KAI is a CRO that relies on cutting edge information technology to help deliver the greatest value to our clients,” states Patti Shugarts, chief operating officer at KAI. She continues: “OpenClinica’s powerful technology and flexible model enable us to deploy a cutting edge EDC that meets the needs of both our industry and government clients.”
The OpenClinica clinical trial software is provided under a commercial open source model, and available in two editions. The OpenClinica Community Edition software is freely available under a widely accepted open source license. The OpenClinica Enterprise Edition consists of a fully validated version of the open source technology with additional capabilities, services, and resource ideal for mission critical research and highly regulated environments. The OpenClinica software is currently in use at over 500 biopharma sponsors, CROs, academic centers, and government agencies worldwide.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
